Literature DB >> 20697805

Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.

Yonglan Zheng1, Jing Zhang, Kisha Hope, Qun Niu, Dezheng Huo, Olufunmilayo I Olopade.   

Abstract

It has been reported that one biallelic missense mutation in the RAD51C gene was found in a Fanconi anemia-like disorder and six monoallelic pathogenic mutations were identified in 480 BRCA1/2 negative breast and ovarian cancer pedigrees but not in 620 pedigrees with breast cancer only. Additionally, the RAD51C gene was reported to be involved in gene fusion events in the MCF-7 breast cancer cell line. We performed complete sequencing and fusion gene breakpoint screening to detect deleterious mutations and chromosomal structure change in the RAD51C gene. Ninety-two hereditary gynecological cancer patients with a family history of breast and ovarian cancer but not carrying BRCA1/2 mutations were studied. In addition, 46 breast cancer cell lines were screened for the gene fusion events. Ten DNA sequence variants but no deleterious mutations were identified. We did not observe the occurrence of the known gene fusion either. We were unable to confirm the contribution of the RAD51C gene to hereditary breast and ovarian cancer (HBOC) in this relatively small cohort. Nonetheless, larger studies in diverse populations to fully investigate the mutation spectrum of the RAD51C gene are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697805     DOI: 10.1007/s10549-010-1095-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Mutation screening of RAD51C in high-risk breast and ovarian cancer families.

Authors:  Wenping Lu; Xianshu Wang; Hongsheng Lin; Noralane M Lindor; Fergus J Couch
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

2.  Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.

Authors:  Nadhir Litim; Yvan Labrie; Sylvie Desjardins; Geneviève Ouellette; Karine Plourde; Pascal Belleau; Francine Durocher
Journal:  Mol Oncol       Date:  2012-09-11       Impact factor: 6.603

Review 3.  Inherited mutations in breast cancer genes--risk and response.

Authors:  Andrew Y Shuen; William D Foulkes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-05       Impact factor: 2.673

Review 4.  Phenotype-genotype correlation in familial breast cancer.

Authors:  Ana Cristina Vargas; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-12       Impact factor: 2.673

5.  BRCA2 is epistatic to the RAD51 paralogs in response to DNA damage.

Authors:  Ryan B Jensen; Ali Ozes; Taeho Kim; Allison Estep; Stephen C Kowalczykowski
Journal:  DNA Repair (Amst)       Date:  2013-02-04

6.  Germline RAD51C mutations confer susceptibility to ovarian cancer.

Authors:  Chey Loveday; Clare Turnbull; Elise Ruark; Rosa Maria Munoz Xicola; Emma Ramsay; Deborah Hughes; Margaret Warren-Perry; Katie Snape; Diana Eccles; D Gareth Evans; Martin Gore; Anthony Renwick; Sheila Seal; Antonis C Antoniou; Nazneen Rahman
Journal:  Nat Genet       Date:  2012-04-26       Impact factor: 38.330

7.  Mutation screening of RAD51C in male breast cancer patients.

Authors:  Valentina Silvestri; Piera Rizzolo; Mario Falchetti; Ines Zanna; Giovanna Masala; Domenico Palli; Laura Ottini
Journal:  Breast Cancer Res       Date:  2011-02-08       Impact factor: 6.466

8.  RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.

Authors:  Florence Le Calvez-Kelm; Javier Oliver; Francesca Damiola; Nathalie Forey; Nivonirina Robinot; Geoffroy Durand; Catherine Voegele; Maxime P Vallée; Graham Byrnes; Breast Cancer Family Registry; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian; Fabienne Lesueur
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

9.  Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.

Authors:  Liisa M Pelttari; Riikka Nurminen; Alexandra Gylfe; Lauri A Aaltonen; Johanna Schleutker; Heli Nevanlinna
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

10.  Inherited and acquired alterations in development of breast cancer.

Authors:  Piera Rizzolo; Valentina Silvestri; Mario Falchetti; Laura Ottini
Journal:  Appl Clin Genet       Date:  2011-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.